SCHEDULE 13D/A: Lipella Pharmaceuticals CEO Jonathan Kaufman Updates 10.1% Beneficial Ownership Stake

Jonathan H. Kaufman, President, CEO, and Chairman of Lipella Pharmaceuticals Inc., has updated his beneficial ownership to 10.1% of the company's common stock, as detailed in Amendment No. 11 to his Schedule 13D filing.

Summary

• Jonathan H. Kaufman, the President, Chief Executive Officer, Secretary, Treasurer, and Chairman of the Board of Directors of Lipella Pharmaceuticals Inc., beneficially owns 212,289 shares of the Issuer's Common Stock.
• This ownership represents 10.1% of the 2,005,244 shares of Common Stock outstanding as of the date of this Amendment No. 11.
• Dr. Kaufman's beneficial ownership consists of 112,352 shares purchased with personal funds and 99,937 shares issuable upon the exercise of fully vested stock options awarded by the Issuer.
• This filing, Amendment No. 11, serves to update Dr. Kaufman's beneficial ownership percentage and does not amend other previously reported information in the Schedule 13D.
• The Reporting Person has not engaged in any transactions with respect to the Common Stock of the Issuer during the sixty days prior to the filing date of this Amendment No. 11.

Sentiment

Score: 5

Explanation: The document is a factual update on beneficial ownership, providing neutral information without explicit positive or negative commentary on company performance or outlook.

Positives

• The President, CEO, and Chairman, Jonathan H. Kaufman, holds a significant beneficial ownership stake of 10.1% in Lipella Pharmaceuticals Inc., indicating strong alignment with shareholder interests.
• A portion of Dr. Kaufman's ownership (112,352 shares) was acquired through personal funds, demonstrating direct financial commitment to the company.

Future Outlook

NA

Industry Context

This filing is a routine insider ownership disclosure for a publicly traded pharmaceutical company. It provides transparency regarding the stake held by a key executive, which is a standard practice in the industry to inform investors about management's alignment with shareholder interests.

Legal Proceedings

• The Reporting Person, Jonathan H. Kaufman, has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) during the last five years.
• The Reporting Person has not been a party to a civil proceeding of a judicial or administrative body that resulted in a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws, or finding any violation with respect to such laws, during the last five years.

Stakeholder Impact

• Shareholders: Provides updated information on the beneficial ownership stake of a key executive, which can influence investor confidence and perception of management alignment.

Key Dates

Keywords

Lipella Pharmaceuticals, Jonathan H. Kaufman, Schedule 13D, Beneficial Ownership, Insider Ownership, Common Stock, SEC Filing, Pharmaceuticals, Biotechnology